Outpatient Cervical Ripening: A Cost-Minimization and Threshold Analysis.


Journal

American journal of perinatology
ISSN: 1098-8785
Titre abrégé: Am J Perinatol
Pays: United States
ID NLM: 8405212

Informations de publication

Date de publication:
02 2020
Historique:
pubmed: 21 8 2019
medline: 1 9 2020
entrez: 21 8 2019
Statut: ppublish

Résumé

To evaluate cost of outpatient (OP) versus inpatient (IP) ripening with transcervical balloons, and determine circumstances in which each strategy would be cost saving. We created a decision model comparing OP and IP balloon ripening in term (≥37 weeks) singleton pregnancies with unfavorable cervix. We performed a cost-minimization analysis and threshold analyses comparing two OP ripening strategies (broad and limited use) to IP ripening from a health system perspective. Base case estimates of probability, utilization, and cost were derived from the literature. The primary outcome was incremental cost of OP versus IP ripening from a hospital perspective. One- and two-way sensitivity analyses explored uncertainty in the model. Both OP ripening strategies were cost saving compared with IP ripening: incremental cost -$228.40/patient with broad use and -$73.48/patient with limited use. OP ripening was no longer cost saving if hours saved on labor and delivery (L&D) were <3.5, insertion visit cost >$714, or facility cost/hour on L&D <$61. Two-way sensitivity analyses showed that OP ripening was cost saving under the most plausible clinical circumstances. In patients with unfavorable cervix, OP transcervical balloon ripening was cost saving under a wide range of circumstances, particularly if OP ripening can shorten time spent on L&D by 3.5 hours.

Identifiants

pubmed: 31430827
doi: 10.1055/s-0039-1694791
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

245-251

Informations de copyright

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Déclaration de conflit d'intérêts

None declared.

Auteurs

Shannon L Son (SL)

Division of Maternal-Fetal Medicine, University of Utah Health, Salt Lake City, Utah.
Division of Maternal-Fetal Medicine, Intermountain Healthcare, Salt Lake City, Utah.

Ashley E Benson (AE)

Division of Maternal-Fetal Medicine, University of Utah Health, Salt Lake City, Utah.
Division of Maternal-Fetal Medicine, Intermountain Healthcare, Salt Lake City, Utah.

Emily Hart Hayes (E)

University of Utah College of Nursing, Salt Lake City, Utah.

Akila Subramaniam (A)

Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama.
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama.

Erin A S Clark (EAS)

Division of Maternal-Fetal Medicine, University of Utah Health, Salt Lake City, Utah.
Division of Maternal-Fetal Medicine, Intermountain Healthcare, Salt Lake City, Utah.

Brett D Einerson (BD)

Division of Maternal-Fetal Medicine, University of Utah Health, Salt Lake City, Utah.
Division of Maternal-Fetal Medicine, Intermountain Healthcare, Salt Lake City, Utah.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH